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Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) in 
which chronic inflammation leads to abnormal deposition of extracellular matrix com-
ponents (ECM) causing obstruction and loss of function of the intestinal tract involved 
(1). Fibrogenesis is mainly regulates by trasforming growth factor (TGF) β/Smad path-
way and a key antagonist of this signaling is represented by peroxisome proliferator-
activated receptor (PPAR)-γ. As the anti-inflammatory drugs currently used in IBD are 
unable to improve intestinal fibrosis the exploration of new therapeutical approaches 
has now became crucial (2). Aim of this study is to evaluate the antifibrotic action of a 
novel PPARγ agonist, GED-0507-34-LEVO (GED), in colon fibrosis in mice.
Chronic colitis and fibrosis were induced in C57BL/6 mice by administration of 
2,5% (w/v) dextrane sulphate sodium (DSS) in drinking water for 5 days followed 
by 7 days of water for 3 cycles. Mice were divided into 3 groups: DSS, DSS+GED and 
control. 30mg/Kg/mice of GED was daily administrated by oral gavage starting from 
the second DSS cycle. Samples from colon were excised and processed to assess mac-
roscopic lesions, histological and morphometrical aspects and immunohistochemical 
and immunoblotting analysis for TGFβ1, CTGF, collagen types I-III, Smad3,α-SMA.
Evident shortening and dilation in the most of colons of DSS treated mice were 
observed. Macroscopic and microscopic findings were significantly improved in 
DSS mice+GED compared with control mice. The tissue levels of collagen and 
α-SMA, specific markers of fibrosis, resulted significantly increased in mice receving 
DSS compared to control mice, as well as the expression of TGFβ1, CTGF, Smad3. 
DSS+GED group showed reduced expression of all markers involved.
GED significantly improves the intestinal fibrotic lesions in DSS chronic colitis 
murine model and controls the pivotal molecular events leading to fibrosis.
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